Yesterday, at the International AIDS Conference (#AIDS2024) in Munich, we got one of those thrilling moments you hope for when attending a scientific conference -- but don't usually get! Here's what happened. @LindaGailBekker @drmoupali https://t.co/dAV7LvUMCj

Looking forward to PURPOSE-2 results in gender-diverse individuals! #preventionwithpurpose

Great write up of the PURPOSE-1 results by @PaulSaxMD highlighting the incredible results and the many innovative aspects of the trial design

👏 @DTHF_SA’s @LindaGailBekker 🇿🇦 receives a standing ovation after presenting full results from the PURPOSE 1 study. The results confirm #lenacapavir demonstrated 100% efficacy for #HIV prevention in cisgender women.

In the PURPOSE 1 randomized, controlled trial involving women in South Africa & Uganda, twice-yearly subcutaneous lenacapavir was superior to daily oral emtricitabine–tenofovir disoproxil fumarate in preventing HIV infection. Full trial results: https://t.co/MMqEYZpszL #AIDS2024

Zero is zero!!! Remarkable results of injectable lenacapavir for PrEP. Now we must translate trial results into public health impact. #AIDS2024 @LindaGailBekker @apha_sa @ICWEastAfrica

“The introduction of oral #PrEP has changed the lives of more than 6 million people globally who have accessed it.” - @iasociety Past President @LindaGailBekker 🇿🇦 #AIDS2024

📊 Today at #AIDS2024, Past IAS President @LindaGailBekker presents full results from PURPOSE 1 trial. The results confirm #lenacapavir demonstrated 100% efficacy for #HIV prevention in cisgender women. Read IAS President & AIDS 2024 Int'l Co-Chair @ProfSharonLewin's statement.

When science listens to community it looks something like this. We Join the AWPCAB and The Purporse1 GGCAG in celebrating the science and most importantly the trial participants . #Purpose1 #Choice #AGYW #AWPCAB https://t.co/UgD5NmcRHx

Gilead's twice-yearly antiviral protected women from HIV infection. PURPOSE 1 study results seem to be fantastic. ⁦@statnews⁩

We are deeply saddened by the passing of Adaora Adimora, MD, MPH, FIDSA. We were incredibly fortunate for her dedication to @IDSAinfo & HIVMA.

Can’t believe the Spurs took Wemby over Podz.

Today is World AIDS Day and after 32 years of living with HIV, I’m blessed to still be here! I’m proud of the progress made in HIV/AIDS research, medication, and funding. We still have a long way to go for a cure and in the fight against stigma in all communities, especially in

lol...this is why my parents made sure I got my driver's license 3 days after I turned 16

#PrEP uptake is suboptimal. One problem is the difficulty providers have in supporting their patients' #sexual well-being. @michael_traeger @JuliaLMarcus @douglaskrakower and I discuss how to prioritize patients' experiences in this week's @LancetHIV https://t.co/TX3prIdSzH

At #IAS2023 symposium on next-generation trial design @drmoupali describes PURPOSE program to study lenacapavir for PrEP — and emphasizes early, committed and consistent community engagement — as per the Good Participatory Practice Guidelines #GPP https://t.co/isPgvFyj6B

@HIVpxresearch @drmoupali @apha_sa @rbaggaley @UNAIDS @LindaGailBekker Research gets it Right when the community is engaged early. When the community is engaged throughout the process. When the community is trusted to deal with complicated challenges faced during trials.

.@GileadSciences' Kathryn Kersey 🇺🇸 outlines the two current trials on lenacapavir (LEN). It is a subcutaneous injection meaning that it could be a self-injection. The trials are looking at the efficacy of LEN as an injectable every 6-months. #IAS2023

Today, we just announced the winners of this year's JIAS Impact Awards! Congratulations to the lead authors of the three selected impactful publications in JIAS in 2022, Kelika Konda and Thiago Torres, Yunia Mayanja, and Nicole McCann. Stay tuned to learn more! #HIV #IAS2023